Dr. Peter McCullough

What we're learning is the biosecurity policy of continuing to cull and destroy all the healthy chickens and just cleanse the facilities and repopulate is allowing the virus to go in and reinfect and reinfect. And it's been too long of a time and it's allowed for genetic misadventure and now potentially some serious strains to emerge.

What we're learning is the biosecurity policy of continuing to cull and destroy all the healthy chickens and just cleanse the facilities and repopulate is allowing the virus to go in and reinfect and reinfect. And it's been too long of a time and it's allowed for genetic misadventure and now potentially some serious strains to emerge.

Chances are they're not, with the exception of SARS-CoV-2. Influenza is known, if you have a whole series of, strains of influenza and they cohabitate in the same nasal pharynx, they can swap genetics because they're all influenza variants. That's called genetic reassortment. Okay. That's the one process. A mutation is when there's a dominant strain and there's a fundamental change.

Chances are they're not, with the exception of SARS-CoV-2. Influenza is known, if you have a whole series of, strains of influenza and they cohabitate in the same nasal pharynx, they can swap genetics because they're all influenza variants. That's called genetic reassortment. Okay. That's the one process. A mutation is when there's a dominant strain and there's a fundamental change.

And with COVID, it's always been the spike protein. That's the big mutation. you know, area where there's change. And in flu, it's the hemagglutinase. That's the spike protein of influenza. So there can be, so this D1.1 mutation of H5N1, that looks like it's a big deal, just like the Delta strain of COVID, the SARS-CoV-2, that was a big deal.

And with COVID, it's always been the spike protein. That's the big mutation. you know, area where there's change. And in flu, it's the hemagglutinase. That's the spike protein of influenza. So there can be, so this D1.1 mutation of H5N1, that looks like it's a big deal, just like the Delta strain of COVID, the SARS-CoV-2, that was a big deal.

And then there's another process that's this kind of seasonal process called antigenic drift. That's a very interesting blend where, you know, in a sense, there is this kind of, seasonal change where there is some variation, you know, animals take on different, you know, images and shapes and humans, you know, over time, it's not the same illness every time. But so we have genetic capabilities.

And then there's another process that's this kind of seasonal process called antigenic drift. That's a very interesting blend where, you know, in a sense, there is this kind of, seasonal change where there is some variation, you know, animals take on different, you know, images and shapes and humans, you know, over time, it's not the same illness every time. But so we have genetic capabilities.

We have a full, uh, you know, genomic sequencing available, but, but don't, don't forget there's also a business opportunity and the business opportunity is always a vaccine.

We have a full, uh, you know, genomic sequencing available, but, but don't, don't forget there's also a business opportunity and the business opportunity is always a vaccine.

And that's the reason why, can you imagine if you're a vaccine manufacturer or let's say you're Bill Gates and you have CEPI, the coalition for epidemic preparedness innovation, and this is your baby, you've invested in this and you, you know, believe, or you could message that there is a strain of pandemic disease, Potential. Oh, so now you're in the vaccine business. This is very important.

And that's the reason why, can you imagine if you're a vaccine manufacturer or let's say you're Bill Gates and you have CEPI, the coalition for epidemic preparedness innovation, and this is your baby, you've invested in this and you, you know, believe, or you could message that there is a strain of pandemic disease, Potential. Oh, so now you're in the vaccine business. This is very important.

And these companies are salivating at the next big government contract for vaccines.

And these companies are salivating at the next big government contract for vaccines.

That's H7N9. Um, and it traditionally had had a higher mortality. Now keep in mind the, the legacy mortality of bird flu was always, you know, Southeast Asia, you know, undernourished families, sleeping with chickens, medical care. It really wasn't plausible. But when we saw that the girl in British Columbia going, you know, modern ICU on ECMO and it looks like, you know, big time,

That's H7N9. Um, and it traditionally had had a higher mortality. Now keep in mind the, the legacy mortality of bird flu was always, you know, Southeast Asia, you know, undernourished families, sleeping with chickens, medical care. It really wasn't plausible. But when we saw that the girl in British Columbia going, you know, modern ICU on ECMO and it looks like, you know, big time,

Bird flu influenza, that caught our attention. The man who died in Louisiana, a little different story. It's still cloudy what's happened. I mean, our CDC needs to go investigate and write up these cases in MMWR.

Bird flu influenza, that caught our attention. The man who died in Louisiana, a little different story. It's still cloudy what's happened. I mean, our CDC needs to go investigate and write up these cases in MMWR.

Well, I should just tell you quickly about the case I just had before I came on with you. And let me tell you that it's a man in his fifties in Dallas, Fort Worth, and he took three Pfizer vaccines. And so the final booster, the final booster was early in 2022. And within a month of the third one, he develops a pulmonary embolism. Okay. So he gets a blood clot. That's a well-known complication of

Well, I should just tell you quickly about the case I just had before I came on with you. And let me tell you that it's a man in his fifties in Dallas, Fort Worth, and he took three Pfizer vaccines. And so the final booster, the final booster was early in 2022. And within a month of the third one, he develops a pulmonary embolism. Okay. So he gets a blood clot. That's a well-known complication of